Background The vast majority of patients with advanced ovarian cancer experience disease recurrence after primary treatment.
Objective To explore the diagnostic accuracy of repeated measurement of patient-reported outcomes and quality-of-life scores in relation to ovarian cancer recurrence.
Methods Patients with ovarian cancer were recruited to the PROMova study by the end of their primary treatment at eight centers in Denmark. The purpose of the PROMova study was to explore the applicability of repeated use of patient-reported outcomes, which consisted of the European Organization for Research and Treatment of Cancer generic questionnaire and the ovarian specific questionnaire. The patient-reported outcomes were completed 3, 6, 9, 12, and 15 months after enrollment or until recurrence. The 3-month interval between completions was the period in which recurrence was assessed. Imaging and the biomarker CA125 were used as reference modality for recurrence. Mixed effects logistic regression was used to investigate the association between mean patient-reported outcome scores and recurrence. Receiver operating curves were used to establish cut-off scores. The diagnostic accuracy of patient-reported outcomes, including sensitivity, specificity, and positive and negative predictive values was estimated based on the Youden index. For combined scales, diagnostic accuracy was investigated based on multivariate analysis.
Results The analysis included 196 patients with an overall recurrence rate of 50.5% and an overall mean time to recurrence of 302 days. With imaging as reference, patients with recurrence reported significantly lower global health, worse physical functioning, and more abdominal symptoms preceding recurrence. With CA125 as reference, global health, physical and emotional functioning were impaired. Despite the worsening of a number of symptoms prior to recurrence whichever reference modality was applied, the patient-reported outcome scores did not provide adequate diagnostic accuracy.
Conclusion Repeated use of patient-reported outcomes during surveillance of ovarian cancer was not of diagnostic value. Future efforts should be directed at improving the administration of patient-reported outcomes as well as exploring the potential of using these outcomes as an indicator of clinical relevance.
- ovarian neoplasms
- quality of life (pro)/palliative care
- medical oncology
Data availability statement
All data are available upon reasonable request.
Statistics from Altmetric.com
Contributors ASK drafted the first version of this article. PTJ, KL, DGH, and KDS revised this article with a substantial contribution. NHH was responsible for the AmbuFlex IT platform. BMK revised the editing of the manuscript. SM was responsible for the data analysis. GIL and NR-J participated with insight into the clinical routines at their departments and patient inclusion.
Funding The PROMova study was financially supported by the Family Hede Nielsen Foundation, the chief physician Jørgen Werner Schou and wife Else Marie Schou, born Wonge Foundation, the Research Council of Lillebaelt Hospital, the Danish Cancer Society (00 262 120), and the Region of Southern Denmark (grant A188).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.